uniQure N.V. Chief Medical Officer Walid Abi-Saab filed a Form 4 on November 3, 2026, disclosing that 18,750 performance-based restricted share units were earned on October 30, 2026 following the satisfaction of certain regulatory milestones.

Key Highlights

  • Reporting person: Walid Abi-Saab, Chief Medical Officer of uniQure N.V. (NASDAQ:QURE)
  • Transaction: 18,750 performance-based restricted share units (PRSUs) acquired on October 30, 2026 at a price of $0
  • Original grant date: PRSUs were granted on January 20, 2026 under uniQure's 2014 Share Incentive Plan, as amended and restated
  • Earning trigger: PRSUs were earned as a result of the satisfaction of certain regulatory milestones, according to the filing
  • Vesting condition: Shares will vest on the later of 10 business days after receipt of certain regulatory clearance or January 20, 2027, subject to continued employment
  • Beneficial ownership following transaction: 166,985 ordinary shares held directly

uniQure CMO Abi-Saab Receives Earned PRSUs Following Regulatory Milestone

According to the Form 4 filed with the SEC on November 3, 2026, Walid Abi-Saab, Chief Medical Officer of uniQure N.V. (NASDAQ:QURE), reported the acquisition of 18,750 ordinary shares in the form of performance-based restricted share units on October 30, 2026. The transaction code is listed as "A" (acquisition), and the price per unit is recorded as $0, consistent with a grant rather than an open-market purchase.

The filing's footnote explains that the PRSUs were originally granted to Abi-Saab on January 20, 2026 under the issuer's 2014 Share Incentive Plan, as amended and restated. The units were earned on October 30, 2026 "as the result of the satisfaction of certain regulatory milestones," as the filing states. Each PRSU represents the contingent right to receive one ordinary share of uniQure N.V.

The filing further notes that the underlying shares will vest on the later of two conditions: first, 10 business days after receipt of certain regulatory clearance, and second, January 20, 2027, in each case subject to Abi-Saab's continued employment by the issuer through the applicable vesting date. Following the reported transaction, Abi-Saab's direct beneficial ownership of uniQure ordinary shares stands at 166,985, as disclosed in the filing. The Form 4 was signed by Christian Klemt as attorney-in-fact on November 3, 2026.

What Was Disclosed

Walid Abi-Saab, Chief Medical Officer of uniQure N.V., reported the earning of 18,750 PRSUs at $0 on October 30, 2026, originally granted January 20, 2026, with vesting contingent on regulatory clearance and continued employment. Post-transaction direct ownership is 166,985 shares.